Zydus Lifesciences' impactful campaign promotes self-breast examination for early detection of breast cancer, reaching ...

The ‘Easiest Exam’ campaign promotes early detection of breast cancer, amassing over 164 million impressions and encouraging ...

Zydus Lifesciences is innovating a single-device for semaglutide. This device can deliver multiple strengths of the drug. It ...

Devan Choksey is bullish on Zydus Lifesciences has recommended buy rating on the stock with a target price of Rs 1069 in its research report dated May 26, 2025.

Zydus Lifesciences has received final approval from the USFDA to launch its isotretinoin capsules USP in six different ...

Ahmedabad: Zydus Lifesciences Limited has received final approval from the United States Food and Drug Administration (USFDA) ...

After a record FY25, the drugmaker sees new growth engines in biologics, vaccines, and devices powering expansion in FY26.

Zydus Lifesciences’ ‘Easiest Exam’ Campaign a public health initiative in breast cancer awareness reaches millions: Our Bureau, Mumbai Monday, May 26, 2025, 15:15 Hrs [IST] ...

EBITDA grew 30% YoY to ₹2,126 crore. By contrast, the company’s EBITDA was ₹1,630.5 crore in the same quarter last year.

Infosys co-founder N. R. Narayana Murthy partners with IIMA to establish a full-fee scholarship, honouring Professor ...

Bajaj Auto and Sun Pharmaceuticals will be some of the other stocks to watch before going into trade on Monday.

Zydus Lifesciences announced that it has received a final approval for Isotretinoin capsules from US Food and Drug Administration (USFDA).